KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Operating Income (2016 - 2025)

Historic Operating Income for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Q4 2025 value amounting to $300.0 million.

  • Teva Pharmaceutical Industries' Operating Income rose 113448.28% to $300.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $2.2 billion, marking a year-over-year increase of 81155.12%. This contributed to the annual value of $2.2 billion for FY2025, which is 81188.12% up from last year.
  • As of Q4 2025, Teva Pharmaceutical Industries' Operating Income stood at $300.0 million, which was up 113448.28% from $882.0 million recorded in Q3 2025.
  • In the past 5 years, Teva Pharmaceutical Industries' Operating Income registered a high of $882.0 million during Q3 2025, and its lowest value of -$967.0 million during Q2 2022.
  • Its 5-year average for Operating Income is $90.4 million, with a median of $189.0 million in 2021.
  • In the last 5 years, Teva Pharmaceutical Industries' Operating Income tumbled by 157692.31% in 2024 and then surged by 920000.0% in 2025.
  • Quarter analysis of 5 years shows Teva Pharmaceutical Industries' Operating Income stood at $78.0 million in 2021, then crashed by 1305.13% to -$940.0 million in 2022, then surged by 180.43% to $756.0 million in 2023, then tumbled by 103.84% to -$29.0 million in 2024, then surged by 1134.48% to $300.0 million in 2025.
  • Its last three reported values are $300.0 million in Q4 2025, $882.0 million for Q3 2025, and $455.0 million during Q2 2025.